Reviewing Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) & Lyell Immunopharma (NASDAQ:LYEL)

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Lyell Immunopharma (NASDAQ:LYEL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Risk and Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500.

Insider & Institutional Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lakefront Biotherapeutics American Depositary Shares and Lyell Immunopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	5	3	0	2.38
Lyell Immunopharma	1	1	6	1	2.78

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $35.50, indicating a potential upside of 16.09%. Lyell Immunopharma has a consensus price target of $40.86, indicating a potential upside of 334.19%. Given Lyell Immunopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Earnings & Valuation

This table compares Lakefront Biotherapeutics American Depositary Shares and Lyell Immunopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.60	$363.05 million	($1.41)	-21.69
Lyell Immunopharma	$27,000.00	8,540.10	-$274.45 million	($12.83)	-0.73

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Lyell Immunopharma. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Lyell Immunopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.